ArrayExpress Uploader0human2.0pancreatic cancer90.02B2.0pancreatic cancer90.01B1.0pancreatic cancer80.02A2.0pancreatic cancer80.02B2.0pancreatic cancer80.02B3.0pancreatic cancer80.02B2.0pancreatic cancer75.01B3.0pancreatic cancer75.02B3.0pancreatic cancer75.02B2.0pancreatic cancer70.02B2.0pancreatic cancer60.02B2.0pancreatic cancer60.02A3.0pancreatic cancer60.02B2.0pancreatic cancer60.02A3.0pancreatic cancer50.02A2.0pancreatic cancer50.02B2.0pancreatic cancer50.02B3.0pancreatic cancer50.02B2.0pancreatic cancer45.02A2.0pancreatic cancer40.02B2.0pancreatic cancer40.02B3.0pancreatic cancer35.02B2.0pancreatic cancer35.02B2.0pancreatic cancer35.02B2.0pancreatic cancer35.02Anannon-malignant pancreasnannannannon-malignant pancreasnannannannon-malignant pancreasnannannannon-malignant pancreasnannannannon-malignant pancreasnannannannon-malignant pancreasnannannannon-malignant pancreasnannan4251arrayexpress_sid4To perform an integrative profile of human pancreatic cancer (PDAC) to identify prognosis-significant genes and their related pathways. A...E-GEOD-32676/profile/8773/arrayexpressuploader432cancercellcompositediseasegenomepancreaspancreatic cancerDec.12, 2014FalseE-GEOD-32676_A-AFFY-44integrative-survival-based-molecular-profiling-ofIntegrative Survival-Based Molecular Profiling of Human Pancreatic Cancer [mRNA]Sep.16, 2014To perform an integrative profile of human pancreatic cancer (PDAC) to identify prognosis-significant genes and their related pathways. A concordant survival-based whole genome in silico array analysis of DNA copy number, and mRNA & micro RNA (miRNA) expression in 25 early stage PDAC was performed. A novel composite score simultaneously integrated gene expression with regulatory mechanisms to identify the signature genes with the most levels of prognosis-significant evidence. The predominant signaling pathways were determined via a pathway-based approach. Independent patient cohorts (n= 150 and 42) were then used as in vitro validation of the array findings. We find that EGFR, SRC signaling, and PI3K/AKT pathway activation are strongly linked to clinical disease progression. Furthermore, we identify two discrete subsets of pancreatic tumors characterized by either SRC or PI3K/AKT signaling that may dictate variable responses to targeted therapy. 42 human PDAC tumors and 7 non-malignant pancreas samples snap-frozen at the time of surgery were chosen. Representative H&E sections of each were evaluated by a practicing gastrointestinal pathologist to confirm diagnosis and determine relative percentage of malignant cells. Samples with tumor cell content >30% were chosen for final multi-platform analysis (N=25). Human pancreatic samples were profiled on Affymetrix HGU133 Plus 2 arrays per manufacturer's instructions.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-32676http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-32676/samples/